These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
5. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061 [TBL] [Abstract][Full Text] [Related]
6. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149 [TBL] [Abstract][Full Text] [Related]
7. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
8. Reduced Gs protein function and G alpha s levels in leukocytes of patients with Parkinson's disease. Avissar S; Barki-Harrington L; Herishanu Y; Schreiber G Mov Disord; 1997 Mar; 12(2):167-74. PubMed ID: 9087974 [TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging. Rinne UK Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903 [TBL] [Abstract][Full Text] [Related]
10. Reduced binding of 3H-spiroperidol to lymphocyte in Wilson's disease. Członkowski A; Członkowska A Acta Neurol Scand; 1984 May; 69(5):298-301. PubMed ID: 6464668 [TBL] [Abstract][Full Text] [Related]
11. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
12. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
13. Decrease in lymphocyte [3H]spiroperidol binding sites in Parkinsonism. Le Fur G; Meininger V; Phan T; Gérard A; Baulac M; Uzan A Life Sci; 1980 Oct; 27(17):1587-91. PubMed ID: 7442460 [No Abstract] [Full Text] [Related]
14. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896 [TBL] [Abstract][Full Text] [Related]
15. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy. Schaefer S; Vogt T; Nowak T; Kann PH; J Neuroendocrinol; 2008 Jan; 20(1):104-9. PubMed ID: 18081558 [TBL] [Abstract][Full Text] [Related]
16. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768 [TBL] [Abstract][Full Text] [Related]
17. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. Blandini F; Mangiagalli A; Martignoni E; Samuele A; Fancellu R; Tassorelli C; Cosentino M; Marino F; Rasini E; Calandrella D; Riboldazzi G; Colombo C; Frigo GM; Nappi G Neurol Sci; 2003 Oct; 24(3):157-8. PubMed ID: 14598064 [TBL] [Abstract][Full Text] [Related]
18. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182 [TBL] [Abstract][Full Text] [Related]
19. [3H]spiperone binding to lymphocyte in extrapyramidal disease and in aging. Członkowska A; Jachowicz-Jeszka J; Członkowski A Brain Behav Immun; 1987 Sep; 1(3):197-203. PubMed ID: 2975511 [TBL] [Abstract][Full Text] [Related]
20. [Relation between autonomic dysfunction and progression of Parkinson's disease]. Oka H; Mochio S; Inoue K Rinsho Shinkeigaku; 2001 Jun; 41(6):283-8. PubMed ID: 11771156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]